Amplia Communications, a privately owned Trinidadian company founded in 2017, provides pay TV services and other telecommunications services across the Caribbean. As of 2023, the company employed approximately 130 people and reported revenues of around $25 million. Its headquarters are located in Trinidad and Tobago.
Amplia Therapeutics reported updated data from its Phase 2a ACCENT clinical trial, evaluating narmafotinib, a FAK inhibitor, in combination with chemotherapy for advanced pancreatic cancer. Recruitment for this trial, which began in January 2024, concluded ahead of schedule in January 2025. The company also shared promising data from the ACCENT trial, showing a 38.5% objective response rate and a median duration on trial of 197 days for the first 26 patients—a 68% improvement over historical data. Top-line data is expected mid-Q3 2025. Additionally, Amplia received feedback from the US Food and Drug Administration (FDA) on its planned US clinical trial for narmafotinib. The FDA deemed proposed protocol changes reasonable, allowing Amplia to finalize the study protocol and begin the final stages of trial planning. This trial will evaluate narmafotinib with FOLFIRINOX chemotherapy in advanced pancreatic cancer patients. The ACCENT trial completed recruitment with 53 patients enrolled two months ahead of schedule.
Similar Companies
Subscribe for full access to Amplia Communications's profile
Amplia Communications offers products in the media and telecoms services industry. Amplia Communications's product portfolio comprises of pay TV services.
Subscribe for full access to Amplia Communications's products in full detail
Amplia Communications's revenues were less than $50M in 2023. Caretta Research has split Amplia Communications's revenue into 2 different product categories, the largest of which is pay TV. For full access to Amplia Communications's revenue breakdown subscribe to Caretta Portal.
Subscribe for full access to Amplia Communications's revenue in full detail
Subscribe for full access to Amplia Communications's products in full detail 
